

UNIVERSITY OF NAPLES NAPOLI “FEDERICO II”

DOCTORATE
MOLECULAR MEDICINE AND MEDICAL BIOTECHNOLOGY
XXIX CYCLE



**Inflammation in chronic degenerative disorders:
A novel CD3⁺CD56⁺ subset that regulates CD8⁺ T cell effector
function.**

**TUTOR:
DONATELLA TRAMONTANO**

**CANDIDATE:
MARIANNA SANTOPAULO**

COORDINATOR

VITTORIO ENRICO AVVEDIMENTO

ACADEMIC YEAR

2015-2016

INDEX

ABBREVIATIONS	3
ABSTRACT	5
1.BACKGROUND	6
1.1Regulation of adaptive immune responses in immune mediated disease	6
1.2 Natural course of type 1 diabetes: genetic and environmental factors contribute in the damage of pancreatic β-cells	9
1.3 Immunopathogenesis of type 1 diabetes: immune mechanisms underlying the selective destruction of pancreatic β-cells	13
2. AIM OF STUDY	16
3. MATERIALS AND METHODS	17
3.1 Cell sorting, immune fluorescence and monoclonal antibodies	17
3.2 Cell culture, CD107/LAMP-1 expression and cytokine production	18
3.3 Proliferation assay	19
3.4 Seahorse experiments	19
3.5 Statistical analysis	20
3.6 T1D subjects	20
3.7 Subjects with prostate cancer	21
4. RESULTS	22
4. Phenotype of CD3⁺CD56⁺lymphocytes	22
4.2 Functional properties of CD3⁺CD56⁺ T lymphocytes	24
4.3 Metabolic programs of freshly isolated CD3⁺CD56⁺ T cells	26
4.4 CD3⁺CD56⁺ cells modulate TCR-dependent cytotoxicity and the production of IFN-γ in cytotoxic CD8⁺ T cells	28
4.5 CD3⁺CD56⁺regulatory activity requires cell to cell contact and is independent on CD56-mediated interactions	34
4.6 T1D subjects show a reduced number and impaired suppressive activity of CD3⁺CD56⁺ cells	37
4.7 Subjects with prostate cancer show a higher number of CD3⁺CD56⁺ cells in peripheral blood	39
5. DISCUSSIONAND CONCLUSION	40
6. ACKNOWELDGMENTS	43
7. REFERENCES	44
7.PUBLICATIONS	51

ABBREVIATIONS:

- T1D: type 1 diabetes
- C-pep: C-peptide
- DCs: dendritic cells
- HLA: human leukocyte antigen
- MHC: The major histocompatibility complex
- HbA1c: glycated haemoglobin
- IAAs: autoantibodies against insulin
- GADA: autoantibodies against the 65-kDa isoform of GAD
- IA-2A: autoantibodies against the protein tyrosine phosphatase-related molecule IA-2
- ZnT8: autoantibodies against the pancreatic β -cell specific protein, zinc transporter 8
- Treg: T-regulatory cells
- NOD mice: non-obese diabetic mice
- NK cells: Natural Killer cells
- NKT cells: Natural Killer-T cells
- APCs: antigen-presenting cells
- CTLs: cytotoxic T lymphocytes
- IFN- γ : Interferon gamma
- TCR: T-cell receptor
- LAMP-1: lysosomal-associated membrane protein-1.
- PTPN22: protein tyrosine phosphatase no receptor type 22
- CTLA-4: Cytotoxic T-Lymphocyte Antigen 4
- IFIH1: Interferon Induced With Helicase C Domain
- IL-2Ra: Interlukin 2 receptor
- CCL1 -2 : CC-chemokine ligand-1 or ligand-2
- PAMP : pathogen-associate molecular pattern
- PRP: pattern recognition receptor

- TME: tumor microenvironment
- ROS: reactive oxygen species
- TNF- α : Tumor necrosis factor
- (TGF)- β : transforming growth factor
- CBV: coxsackie B viruses
- NO: nitric oxide.

Abstract

It has been reported that a growing and heterogeneous group of regulatory cell modulate immune response. In particular, regulation of CD8⁺ T lymphocyte effector functions is critical for tissue homeostasis and immune tolerance control. Here, we report that the co-expression of CD3 and CD56 molecules identify a novel human regulatory T cell population exerting suppressive activity on proliferation, cytotoxicity and IFN- γ production of TCR-activated human CD8⁺ T lymphocytes. Regulatory functions of human circulating CD3⁺CD56⁺ T lymphocytes require cell-to-cell contact and are exerted in both autologous and allogeneic conditions. Of note, CD3⁺CD56⁺ T cells are reduced and functionally impaired in children affected by Type 1 Diabetes (T1D), at disease onset. Conversely the frequency of this cell subset is increased in patients with prostate cancer.

Taken together, our findings reveal that freshly isolated human CD3⁺CD56⁺ cells specifically control activation of human CD8⁺ T lymphocytes. Perturbation of number and function of this cell subset may account for the deranged functions of CD8⁺ T lymphocytes observed in autoimmune conditions, including T1D. Thus, therapeutic manipulation of CD3⁺CD56⁺ cells may represent an innovative approach to restore immune function in T1D.

1. BACKGROUND

1.1 Regulation of adaptive immune responses in immune mediated disease

The immune response is a complex phenomenon aimed to confer protection against pathogens and simultaneously maintain tissue homeostasis. Immune response also includes the establishment of immunologic memory and clearance of transformed cells. All of these functions share many common interactive pathways responsible for early triggers of the host immune response as well as modulate immune functions. It has been reported that alterations in these pathways can lead to a variety of both organ specific and systemic autoimmune syndromes, including Type 1 Diabetes (T1D). Aberrant regulatory activity also favors tumor escape from effector immune mechanisms. The key role of regulatory T lymphocytes in the prevention of autoimmunity and immune mediated diseases has been largely shown¹⁻². Fine-tuning of immune response is usually obtained by multiple regulatory processes, all belonging to the immune tolerance network, that are in place to prevent potentially deleterious immune responses against self tissues³⁻⁵.

Regulatory cells represent a heterogeneous group of differentiated T cell subsets including the interleukin (IL)-10 producing Tr1, the transforming growth factor (TGF)- β producing T helper 3 (Th3) and the CD25⁺CD4⁺ regulatory T (Treg) cells, constitutively expressing the forkhead box P3 (Foxp3) transcription factor⁶⁻⁸. CD4⁺CD25⁺Foxp3⁺ Treg cells control the immune-effector response in terms of clonal expansion, differentiation, cytokine profile and tissue migration during immune response and are indispensable for the maintenance of immune self-tolerance⁹. CD8⁺ T regulatory clones have been also described, but their role and phenotype features are still undefined¹⁰⁻¹¹. It is not clear whether different CD8⁺ regulatory cells represent an independent T subset or if they reflect the dynamic plasticity of a single population. Human CD8⁺Tregs have been implicated in various inflammatory disorders in association with autoimmunity, including T1D, infectious disease and cancer¹²⁻¹⁵. These CD8⁺ cells may exert their activity through different mechanisms. Literature indicates that CD8⁺CD28⁻ T lymphocytes can suppress T helper (Th)-1 cells, induce CD4⁺ T-cell anergy and regulate reactivation of T cells^{11,16-17}. Furthermore, antigen-induced CD8⁺CD103⁺ regulatory T cells have been shown to suppress T cell effector functions in models of transplantation tolerance¹⁸. Moreover, it has been also observed that CD8⁺ Treg cells modulate

immune response *in vivo* by suppressing activated CD4⁺ T cells *via* cell-cell contact dependent mechanisms requiring CD11a/CD18 (LFA-1) expression¹⁹. Recent studies suggest that CD8⁺ CD25hi (IL-2R α chain) Foxp3⁺ Treg cells, like CD4⁺ CD25hi Foxp3⁺ cells, suppress immunity via cytokine production including IL-10²⁰⁻²¹. Conversely, CD8⁺ CD122hi (IL-2R β chain) Treg cells produce IL-10 to suppress CD8⁺ T cell effector functions²². CD8⁺ T lymphocytes are one of the major adaptive immune cells, and play important role in maintaining immune homeostasis. Some different clinical studies have established that CD8⁺ T cells can profoundly affect cancer progression. After stimulation, CD8⁺ T cells exert functional activity through the release of cytotoxic granules that lyse target cells, as well as by the production of interferon (IFN)- γ ²²⁻²³. When hyper-activated these cells release large amounts of pro-inflammatory cytokines, which are directly involved in disease pathogenesis. Importantly, so far, targeting of CD8⁺ T cells by specific regulatory populations is unexplored.

Several evidence indicate that alteration of molecular mechanisms at the basis of immune response accelerate the course of chronic diseases, including cancer^{5,24-25}. In the tumor microenvironment (TME), T cells have an altered phenotype and aberrant functions. The role of CD4⁺ and CD8⁺ Treg cells have been extensively elucidated in many different types of cancer²⁶⁻³⁰. Specifically, in tumor-infiltrating lymphocytes (TILs); the decreased ratios of intraepithelial CD8⁺ T cells to FOXP3⁺CD25⁺CD4⁺ Treg cells is associated with poor prognosis in ovarian, breast, and gastric cancers³⁰. Furthermore, recent data indicate that CD8⁺Foxp3⁺Treg cells present in prostate cancer among TILs are able to suppress anti-cancer immune responses³¹.

Over the past years, a number of observations indicate that normal peripheral blood of healthy individuals contains a small lymphocyte population co-expressing CD56 and CD3 surface markers that characterize human natural killer (NK) and T (CD3) cells, respectively³².

Although the biological hallmarks and functional characteristics of CD3⁺CD56⁺ cells are not completely defined and experimental evidence associated these cells with different pathophysiological conditions. Indeed, significant decrease of hepatic recruitment of CD3⁺CD56⁺ cells has been found after liver transplant with high rejection activity, while high circulating number of CD3⁺CD56⁺CD16⁺ cells has been described to predict a better *in vitro* fertilization

(IVF) treatment outcome³³⁻³⁴. Moreover, a positive correlation between CD3⁺CD56⁺ lymphocyte frequency and the serum hepatitis B viral DNA level was observed during early antiviral therapy³⁵⁻³⁶. Also, it was described a Foxp3⁺CD3⁺CD56⁺ population with immunosuppressive function in human hepatocellular carcinoma³⁷⁻³⁸. Recently, it was been shown that the absolute number of circulating CD3⁺CD56⁺ T cells represent a valuable predictive marker of β -cell residual function up to one year after T1D diagnosis. Specifically, the high CD3⁺CD56⁺ T numbers, at disease onset, are associated with a higher β -cell activity in T1D one year later³⁹. In addition, *Hu et al.* identified in human peripheral blood the CD3⁺CD56⁺CD8⁺CD161⁻ population able to kill autologous CD4⁺ T cell upon T cell receptor (TCR) engagement⁴⁰. However, the possible involvement of CD3⁺CD56⁺ cells in immune-tolerance control has been poorly investigated.

Here we describe that freshly isolated human CD3⁺CD56⁺ cells are an heterogeneous cell population, containing both CD4⁺ and CD8⁺ T cells, able to specifically modulate proliferation, cytotoxic function and cytokine production of T cell-receptor (TCR) activated CD8⁺ T cells. Moreover, T1D children at diagnosis display reduced circulating number and impaired suppressive activity of CD3⁺CD56⁺ T cells. In contrast in subjects with prostate cancer, we observed an increase of circulating CD3⁺CD56⁺ that correlates with prognosis score.

1.2 Natural course of type 1 diabetes: genetic and environmental factors contribute in the damage of pancreatic β cells

T1D is a severe chronic disease characterized by the progressive autoimmune destruction of the insulin-secreting β -cells in the pancreas of genetically susceptible individuals. Insulin is a hormone that helps move sugar, or glucose, into body's tissues. When pancreatic cells are damaged, they are not able to produce insulin, glucose cannot be moved out of bloodstream into cell, and the blood sugar levels become high. The etiology of the disease is unclear but genetic, immunological and environmental factors act together to participate the disease pathogenesis. (Fig. 1)




Fig.1 Environmental triggers, immunological and genetic factors influence the development of islet autoimmunity and progression to clinical diabetes. Discov Med. 2010

Genetic risk is largely conferred by strongest association between T1D and the human leukocyte antigen (HLA) class II haplotypes of HLA-DR and HLA-DQ located within the major histocompatibility complex (MHC) on chromosome 6p21⁴¹⁻⁴². The most common combinations of HLA genes present in children in whom the disease develops very early in life are DR4-DQ8 and DR3-DQ2, commonly present in 90% of children with T1D. A third haplotype, DR15-DQ6, is found in less than 1% of children with T1D, compared with more than 20% of the

general population, and is considered to be protective⁴³. It has been reported that majority of genes associated to T1D risk encode proteins that are involved in immune function and regulation; for example, protein tyrosine phosphatase, non-receptor type 22 (PTPN22), Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4), Interferon Induced With Helicase C Domain 1 (IFIH1) and Interleukin 2 receptor α (IL-2Ra) which regulate lymphocytes signalling and T cell tolerance⁴⁴⁻⁴⁵. Interestingly, recent evidences suggest that HLA genes primarily contribute to development of autoantibodies, while non-HLA genes and environmental factors may be more important in the progression from autoantibodies to clinically overt disease⁴⁶⁻⁴⁷. In T1D the progressive destruction of pancreatic β -cells begins before the clinical manifestation. This phase is usually asymptomatic or characterized by metabolic disturbances. The natural course of T1D is characterized by transient restoration of β -cell function. This phase is common called “honeymoon period” and it is characterized by a reduction of the daily exogenous insulin requirement while good metabolic control is maintained. When most of the β -cell mass is lost, clinical signs of chronic hyperglycemia become evident and consequently patients need frequent blood glucose testing and daily insulin replacement therapy. Different metabolic and clinical factor, including age of presentation, degree of metabolic decompensation at diagnosis and the presence of autoantibodies, are able to influence frequency and the duration of “honeymoon period”.

The natural history of T1D has improved through the combined use of genetic, autoantibody, and metabolic markers of the disease. Autoimmunity in T1D has typically been identified by the presence of autoantibodies to islet or β -cell antigens. The autoantibodies are not directly pathogenic but are biomarkers of the development of autoimmunity⁴⁶⁻⁴⁹. **(Fig. 2)**

The development of an autoimmune process against Langerhans islets is characterized by the appearance of islet autoantibodies, which can be measured in the serum of these subjects. **(Fig. 2)** Islet autoantibodies identified so far include those against insulin (IAAs), the 65-kDa isoform of GAD (GADA), the protein tyrosine phosphatase-related molecule IA-2 (IA-2A), and more recently autoantibodies against the pancreatic β -cell specific protein, zinc transporter 8 (ZnT8)⁵⁰⁻⁵¹. The risk of developing diabetes is related to the number of detectable autoantibodies with different specificities, which suggests that spreading of the autoantigenic repertoire is part of the pathogenic process. Once islet autoantibodies

have developed, the progression to overt diabetes in autoantibody-positive individuals is determined by the age of antibody appearance and by the magnitude of the autoimmunity, in turn related to the age of the subject⁵². (Fig. 2)




Fig. 2 Natural course of the immunopathogenesis of T1D. *Physiol Rev.* 2011

Candidate risk factors operating during infancy include those related to exposure to infectious agents, improved hygiene and mucosal exposure to dietary constituents. Enteroviruses, particularly coxsackie B viruses (CBV), are currently considered as the prime candidate among infectious agents by nature of their tropism for β-cells⁵⁶⁻⁵⁶. In addition, experiments using isolated human islets have shown that CBVs are able to infect and replicate in insulin-producing β-cells⁵⁷. In contrast to the infectious hypotheses is the notion that improved hygiene is responsible for increased of T1D incidence⁵⁸⁻⁶¹.

Overall, several environmental factors seem to modify the risk of islet autoimmunity and T1D and have been considered to trigger autoimmune responses against pancreatic β-cells, eventually leading to β-cell destruction. The heterogeneity of T1D progression and clinical manifestations is likely a reflection of this complex multifactorial pathogenesis. Among environmental factors, several evidences point to infectious agents, components of early childhood diet and gut

microbioma. Finally, besides the “classical” triggers (infections, diet, gut), growing evidence points at inflammation and metabolic changes as significant cofactors in T1D pathogenesis⁶².

1.3 Immunopathogenesis of type 1 diabetes: immune mechanisms underlying the selective destruction of pancreatic β -cells

Dysregulation of the immune system contributes to the breakdown of immune tolerance, leading to T1D. It is well known that initiation of T1D requires both CD4⁺ and CD8⁺ T cells, where autoreactive T cells differentiate into effectors by engaging β -cell antigens presented by antigen-presenting cells (APCs)⁶³. In early onset diabetes, CD8⁺ T cells are the most abundant pancreas-infiltrating cells during insulinitis⁶⁴⁻⁶⁶. It has been reported that β -cell failure is caused by lymphocytic infiltration of the isle by dendritic cells (DCs), T lymphocytes, macrophages, B cells and natural killer cells⁶⁷⁻⁶⁹. Published evidences have been described a pathogenic additional role of macrophages in both the initiation and destruction phases of T1D. Recruitment of macrophages to islets is mediated chemokines produced mainly by CD4⁺ T cells and pancreatic β -cells. Macrophages recruited to the pancreas produce IL-1 β and Tumor Necrosis Factor (TNF)- α and reactive oxygen species (ROS) that can promote β -cell death. In particular, the TNF- α and IL-1 β produced by macrophages and DCs have been observed in pancreatic islet infiltrates from patients with recent-onset T1D⁷⁰. Finally, macrophages have been shown to produce IL-12 and to promote efficient differentiation of diabetogenic CD8⁺ cytotoxic T lymphocytes (CTLs)⁷¹⁻⁷². Also, recruitment of macrophages to islets is mediated by the secretion of CC-chemokine ligand 1 (CCL1) by CD4⁺ T and CCL2 produced by pancreatic β -cells⁷³. Furthermore, insulin-autoreactive CD4⁺ T cells have also been described in T1D patients and some studies indicated that high-avidity insulin-reactive thymocytes may evade central tolerance in patients⁷⁴. CD4⁺ T lymphocytes play an important role in the activation and proliferation of CD8⁺ T lymphocytes and B cells⁷⁵⁻⁷⁷. B cells present MHC class I-peptide complexes to self-reactive CD8⁺ T cells, that resulted in the proliferative expansion of self-reactive CTL in the pancreatic lymph nodes (PLNs) and the acquisition of a cytotoxic phenotype with a capacity to destroy β -cells⁷⁸⁻⁷⁹. NK cells are also involved in T1D pathogenesis; indeed, these cells are cytotoxic and produce cytokines, particularly IFN- γ , that could contribute to the destruction of β -cells^{53,80-81}. Insulin-producing cells are sensitive to the action of this cytokine and IFN- γ can also promote cell death through NO synthesis and

induce cell-surface Fas receptor (Fas) expression on β -cells, favoring cell apoptosis. In addition, TNF- α can promote β -cell apoptosis through the Fas/Fas-Ligand (FasL) pathway, in addition it influences the production of the cytotoxic molecules by CD8⁺ lymphocytes⁸²⁻⁸⁵. Normally, CD8⁺ T cells effector function protect against viruses and contribute to eliminate tumor cells. In particular, in T1D this is achieved through TCR/CD8 recognition of peptide complex presented by major histocompatibility complex (MHC) class I molecules express on pancreatic β cells, resulting in the cytotoxic targeting of abnormal or infected cells. Upon recognition of antigen, naïve CD8⁺ T cells were activated to proliferate and differentiate into cytokine producing effectors or CTL and undergo clonal expansion and respond to infection⁸⁶⁻⁸⁹. In addition, effective CTL immunity is associated with long-term protection against chronic or subsequent exposure to the virus or tumor, through the stable induction of antigen-specific CD8⁺ T cell memory⁹⁰⁻⁹¹. Activated effector cells then migrate to peripheral tissues and after recognition of antigen target the cells for destruction. Killing of target cells by CTLs is mediated through two major pathways, release of cytolytic granules containing granzyme B and perforin resulting in direct lysis of target cells, and induction of Fas signaling, leading to cytolysis via the activation of a death domain and a caspase apoptosis cascade. In patients with autoimmune hepatitis, FasL and granzyme B levels are elevated in the liver, suggesting a role for CTLs in hepatocyte apoptosis and liver damage⁹²⁻⁹⁵. Alterations of these pathways are observed in different autoimmune conditions **(Fig. 3)**.




Fig. 3 Immunological mechanisms involved in the pathogenesis of T1D. Nat Rev Immunol. 2010

2. AIM

T1D results from autoimmune damage of insulin producing β -cells in the islets of Langerhans, in the pancreas. The development of the T1D is determined by alteration of mechanisms that mediate immune tolerance, resulting in the expansion of islet-reactive $CD4^+$ and $CD8^+$ T effector (Teff) cells and subsequent β -cell destruction. In particular, autoreactive $CD8^+$ T cells play a central role in the destruction of pancreatic islet β cells that leads to T1D.

T cells with regulatory properties have been shown to be involved in the pathogenesis of immune mediated disorder³⁻⁵. However, to date, specific regulation of $CD8^+$ T cell function is still largely unexplored. Over the past years, a number of observations indicate that normal peripheral blood contains a small population of cells that express both CD56 and CD3 phenotypic markers (here defined as $CD3^+CD56^+$ cells) that characterize human natural killer (NK) and T (CD3) cells, respectively. Experimental evidence associated this subset with different pathophysiological conditions³⁶. Indeed, significant decrease of hepatic recruitment of cells has been found after liver transplant with high rejection activity³². Recent data have shown that the absolute number of circulating $CD3^+CD56^+$ T cells represents a valuable predictive marker of β -cell residual function up to one year after T1D diagnosis³⁹. Importantly, no study so far has examined the biological hallmarks and functional characteristics of $CD3^+CD56^+$ cells. In this study, we aim at analysing the possible immune regulatory role of $CD3^+CD56^+$ cells in healthy controls and in pathological conditions such as T1D. Possible results of our study may unveil an additional regulatory subset involved in the control of immune tolerance.

We hypothesized that $CD3^+CD56^+$ cells represent a novel regulatory population that control specifically the effector functions of $CD8^+$ cells, the main effectors for the destruction of β -cells during T1D⁶⁵.

Perturbation of the number and function of $CD3^+CD56^+$ cells may account for the deranged functions of lymphocytes $CD8^+$ T observed in T1D. Therapeutic manipulation of $CD3^+CD56^+$ cells may represent an innovative approach to restore immune tolerance in immune mediated disorders.

3. MATERIAL AND METHODS

3.1 Cell sorting, immune fluorescence and monoclonal antibodies

CD3⁺CD56⁺, CD3⁻CD56⁺, CD3⁺CD8⁺ and CD3⁺CD4⁺ cells were isolated, after Ficoll hypaque–gradient centrifugation (GE-Healthcare), from PBMCs of human healthy donors and T1D subjects by high-performance cell sorting (BD FACS-Jazz, BD Bioscience) in the IEOS-CNR Sorting Facility in Napoli, after staining with the following antibodies: FITC anti-human CD3 (BD PharMingen, clone UCHT1), PE-Cy7 anti-human CD56 (BD PharMingen, clone B159), FITC anti-human CD4 (BD PharMingen, clone RPA-T4), APC anti-human CD8 (BD PharMingen, clone RPA-T8) or by magnetic cell separation with microbeads CD3⁺CD56⁺ isolation Kit (Miltenyi Biotec). Sorted cells were 95%–98% pure by FACS analysis. Buffy coats from control healthy subjects were obtained after they signed an IRB-approved written informed consent. Samples were analyzed by immunofluorescence and Flow Cytometry by using a two laser equipped FACSCanto II (BD PharMingen). FITC, PE, PE-Cy7, PE-Cy5, APC-H7 and APC-labeled mAbs against CD3 (BD Pharmingen, clone UCHT1); CD4 (BD PharMingen, clone RPA-T4), CD8 (BD PharMingen, clone RPA-T8), CD16, (BD PharMingen, clone CLB/FcGran1), CD45 (BD Pharmingen, clone 2D1), CD25 (BD Pharmingen, clone M-A215), CD39 (BD Pharmingen, clone TU66), CD49d (BD Pharmingen, clone 9F10), CD45RA (BD Pharmingen, clone L48) CD45RO (BD Pharmingen, clone UCHL1), CD54 (BD Pharmingen, clone HA58), CD56 (BD Pharmingen, clone B159), CD57 (BD Pharmingen, clone HNK-1), CD62L (BD Pharmingen, clone SK11), CD69 (BD Pharmingen, clone L78), CD107/LAMP-1 (BD Pharmingen, clone H4A3), CD94 (BD Pharmingen, clone HP-3D9), CCR7 (BD Pharmingen, clone 15503), CTLA-4 (BD Pharmingen, clone BNI3) CXCR4 (BD Pharmingen, clone 12G5) Foxp3 (ebioscience, clone 259D/C7), GITR (Miltenyi, clone DTA-1), DNAM-1 (BD Pharmingen, clone DX11), PD-1 (BD Pharmingen, clone EH12.1), IFN- γ (BD Pharmingen, clone B27), NKG2A (Beckman Coulter, clone Z199), NKp30 (Beckman Coulter, clone Z25), NKp46 (Beckman Coulter, clone BAB281), CD1d:Ig fusion protein (BD Pharmingen), V α 24 (Beckman Coulter, clone C15) and isotype-matched controls

all from BD Pharmingen. FITC and PE labeled mAbs against TCR V β epitopes, namely anti-V β 1, V β 2, V β 3, V β 4, V β 5.1, V β 5.2, V β 5.3, V β 7.1, V β 8 V β 9, V β 11, V β 13.1, V β 13.2, V β 13.6, V β 14, V β 16, V β 17, V β 20, V β 21.3 V β 22, V β 23. To analyze the production of Interferon (IFN)- γ purified cells intracellular staining with the specific mAb was performed by using the fixing/permeabilization (Caltag 554722), following the manufacturer's instructions. To avoid extracellular cytokine export, the cultures were performed in the presence of 5 μ g/ml of Brefeldin-A (Sigma-Aldrich), as described⁵⁰. Analysis was performed by using FlowJo Software (Tree Star). The control 345.134 IgG2a mAb, recognizing a glycoprotein widely expressed on human leucocytes⁵¹ was a kind gift of Dr. S. Ferrone; recombinant human soluble NCAM-1/CD56 molecule was purchased from R&D Systems, Inc.

3.2 Cell culture, CD107/LAMP-1 expression and cytokine production

To obtain IL-2PBMC or IL-2CD8⁺ cells, PBMC or flow sorted CD8⁺ T cells were cultured for 48 hours in RPMI-1640 (Life Technologies) supplemented with 5% AB human serum in the presence of recombinant human IL-2 (Sigma) at 100UI/ml. IL-2PBMC or IL-2CD8⁺ cells were incubated for 4 hours with anti-CD3 plus anti-CD28 mAb-coupled microbeads (Life Technologies) at the cell/bead ratio of 1:1 or with the K562 cell line (ATCC) at 1:1 ratio. CD107/LAMP-1 expression and IFN- γ production were evaluated in flow cytometry gated CD3⁺CD56⁻, CD3⁺CD56⁺, CD3⁻CD56⁺ (NK cells), CD4⁺ and CD8⁺ T cells, as indicated. When indicated IL-2PBMC or IL-2CD8⁺ cells were co-cultured with fresh isolated with CD3⁺CD56⁺, CD3⁻CD56⁺ (NK cells) and CD3⁺CD8⁺ lymphocytes at different ratio. Brefeldin-A (BFA) at 5 μ g/ml (Sigma) was added in the last three hours of culture for CD107/LAMP-1 staining or for the whole culture period for IFN- γ production^{30,50}. Short term-cell lines were obtained culturing flow sorted CD3⁺CD56⁺ or CD3⁺CD56⁻, in the presence of anti-CD3 plus anti-CD28 mAb-coupled microbeads (0.2 beads/cell) with regular supplementation of hrIL-2 (20 UI/ml) for 10 days. To avoid cell-cell contact, coculture of CD3⁺CD56⁺ with IL-2CD8⁺ lymphocytes was performed by using transwell inserts (Corning Life Sciences).

3.3 Proliferation assay

For the assessment of cell proliferation, cells were cultured in the presence of microbeads coated with anti-CD3 plus anti-CD28 (Life Technologies) at the cell/bead ratio of 0.1:1, as previously indicated⁹⁶. Cultures were incubated for 72 hours at 37°C in a humidified atmosphere containing 5% CO₂ and pulsed with 0.5 µCi/well [³H] thymidine for the final 16 hours. The incorporation of the labeled nucleotide was determined by scintillation counting after automatic cell harvesting. All tests were performed in the presence of RPMI 1640 Medium supplemented with 5% heat inactivated 5% AB human serum (Invitrogen).

3.4 Seahorse experiments

Metabolic profile was evaluated in CD3⁺CD56⁺, CD3⁻CD56⁺ and CD3⁺CD4⁺, in the absence or in the presence of anti-CD3 plus anti-CD28 microbeads (0.1 beads/cell) (Invitrogen). Real time measurements of oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) were made by an XF-96 Extracellular Flux Analyzer (Seahorse Bioscience). Specifically, cells were plated in XF-96 plates (Seahorse Bioscience) at the concentration of 2 x 10⁵ cells/well and cultured with RPMI-1640 medium supplemented with 5% AB human serum. OCR was measured in XF media (non-buffered DMEM medium containing 10 mM glucose, 2 mM L-glutamin, and 1 mM sodium pyruvate), under basal conditions and in response to 5 µM oligomycin, 1.5 µM of carbonylcyanide-4-(trifluoromethoxy)-phenylhydrazone (FCCP) and 1 µM of antimycin and rotenone (Sigma Aldrich). ECAR was measured in XF media in basal condition and in response to 10 mM glucose, 5 µM oligomycin and 100 mM of 2DG (all from Sigma Aldrich). Experiments with the Seahorse were done with the following assay conditions: 3 minutes mixture; 3 minutes wait; and 3 minutes measurement.

3.5 Statistical analysis

Statistical evaluation of data, by *InStat 3.0* software (GraphPad Software Inc., San Diego, California, USA), was performed by Mann-Whitney test, as indicated. Two-sided p values less than 0.05 were considered significant.

3.6 T1D subjects

The study was approved by the Institutional Review Board (IRB) of the Università degli Studi di Napoli “Federico II”. Prot N. 200/16.

Recruitment of T1D patients (8 ± 7 years age, in a females:males ratio of 1:1), with glucose values between 80-180 mg/dl, after glycemic stabilization on exogenous insulin, achieved in 5 days. Diagnosis of T1D was defined according to the Global International Diabetes Federation/International Society for Pediatric and Adolescent Diabetes Guidelines for Diabetes in Childhood and Adolescence⁹⁷ and included symptoms of diabetes in addition to casual plasma glucose concentration ≥ 11.1 mmol/L (200 mg/dl), or fasting plasma glucose ≥ 7.0 mmol/l (≥ 126 mg/dl), or 2 hours postload glucose ≥ 11.1 mmol/l (≥ 200 mg/dl) during an oral glucose tolerance test, and glycated hemoglobin (HbA_{1c}) ≥ 6.5 .⁹⁷ The criteria used to select healthy control subjects for T1D studies were the following: fasting blood glucose of < 5.5 mmol/L (< 100 mg/dl), negative personal and familial history of autoimmune disorders, and negativity for islet autoantibodies at the 99th percentile. The T1D children and control subjects (matched for age, sex and BMI) were recruited at the Dipartimento di Scienze Mediche Traslazionali, Sezione di Pediatria Università di Napoli “Federico II”, after the IRB of the Università degli Studi di Napoli “Federico II” approved the study and parents gave their written informed consent.

3.7 Subjects with prostate cancer

In this study, we analysed the frequency of human of CD3⁺CD56⁺ T lymphocytes, isolated from peripheral blood of subjects with prostatic cancer are higher (n=10) compared to normal blood collected from healthy individuals as the control group, (n=12). PBMC were isolated using Ficoll-Paque density gradient centrifugation, from subjects with prostatic cancer. The cell suspension were then used for flow cytometry analysis. PBMC were stained with anti-CD3 BV510, anti-CD56 PE-CY7 and anti CD45 APC-H7. All antibodies were purchased from BD eBiosciences, (BD eBioesciences, USa). Samples were analyzed on BD FACS Canto II and the frequency of CD3⁺CD56⁺ T lymphocytes were calculated and compared with healthy controls. Actually, the Gleason grading system for prostatic carcinoma is the dominant method around the world in research and in daily practice. Here we correlate the frequency of CD3⁺CD56⁺ T lymphocytes with Gleason grade prostate cancer.

4. RESULTS

4.1 Phenotype of CD3⁺CD56⁺ T lymphocytes

In order to evaluate the phenotype of human CD3⁺CD56⁺ T cells, we analyzed the expression of several T and NK cell-associated markers in CD3⁺CD56⁺, CD3⁺CD56⁻ and CD3⁻CD56⁺ (NK) cells. As shown, CD3⁺CD56⁺ cells expressed, at different levels, T cell markers and the analysis of CD45 isoforms shows that CD3⁺CD56⁺ subset preferentially expressed CD45RA molecule, while they not showed surface molecules usually associated with NK, including NKG2A, CD94, Nkp46, DNAM-1 and TCR-V α 24 chain. (**Fig. 1**). The absence of TCR-V α 24/V β 11 chains indicate that CD3⁺CD56⁺ T lymphocytes did not belong to the NKT cell subset (**Fig. 1**). In addition, CD3⁺CD56⁺ cells expressed the TCR α and β chains, with a heterogeneous repertoire of V β gene families, similar to that observed in CD3⁺CD56⁻ T cell population (**data not shown**). Moreover, CD3⁺CD56⁺ cells did not express the common Treg cell-specific markers, including CD25, Foxp3, GITR, CTLA-4, CD39 and PD-1 (**data not shown**). The expression of CD54, CD57, CD62L CD16, CD49d, HLA-DR, and of the chemokine receptors CCR7 and CXCR4 were also analyzed in CD3⁺CD56⁺ cells (**data not shown**).




Fig. 1 Phenotype of CD3⁺CD56⁺ human lymphocytes. (a) Flow cytometry of peripheral blood from one representative healthy control. Upper panel indicates the gating strategy to define NK, CD3⁺CD56⁺ and CD3⁺CD56⁻ cell subsets, showing the characteristic phenotype of these cell subsets. Expression of several molecules usually associated with NK, T and (i)NKT cells are reported.

4.2. Functional properties of CD3⁺CD56⁺ T lymphocytes

To investigate the functional properties of CD3⁺CD56⁺ cells, we evaluated their proliferation, IFN- γ production and cytotoxic ability through the expression of Lysosomal-Associated Membrane Protein-1 (LAMP-1/CD107a), after stimulation with either TCR or NK-dependent stimuli. To determine the proliferative response of this cell subset, flow cytometry sorted CD3⁺CD56⁺ cells were stimulated for 72 hours with anti-CD3 plus anti-CD28 mAbs. We found that these cells had reduced proliferative ability compared with CD4⁺ and CD8⁺ conventional T (Tconv) cells. **(Fig. 2a)** To evaluate the functions of CD3⁺CD56⁺ subset, we cultured PBMCs for 48 hours in the presence of human recombinant IL-2 (hrIL-2) to obtain IL-2PBMC. This condition has been described to optimize both cytotoxic activity and IFN- γ production⁹⁸. We observed that, co-culture for 4 hours of IL-2PBMC with K562 cell line, that represents a prototypic NK-target, was unable to induce CD107a/LAMP-1 expression and IFN- γ production in both CD3⁺CD56⁺ and CD3⁺CD56⁻ cells **(Fig. 2b)**. As expected, CD107a/LAMP-1 expression and IFN- γ production were observed in NK lymphocytes. In contrast, after TCR activation of IL-2PBMC with microbeads coated with anti-CD3 plus anti-CD28 mAbs, cytotoxicity and IFN- γ production were detected in both CD3⁺CD56⁺ and CD3⁺CD56⁻ cells⁹⁹ **(Fig. 2c)**. As expected, NK cells did not respond to TCR stimulation.

Together, these results indicated that human CD3⁺CD56⁺ cells showed phenotypic and functional profile similar to that observed in CD3⁺ T lymphocytes.





Fig. 2 (a) Thymidine incorporation (cpm) of CD3⁺CD56⁺ cells compared with CD4⁺ (orange line), CD8⁺ (green line) T cells, and NK (magenta line). Data are from seven independent experiments (mean \pm S.E.M) (b) Upper panels show results of CD107a/LAMP-1 and IFN- γ staining profiles of CD3⁺CD56⁻ (black line), CD3⁺CD56⁺ (blue line), NK (magenta line), after four hours of culture in the presence of K562 cell line (plain line). (c) Lower panels indicate CD107a/LAMP-1 and IFN- γ staining profile of CD3⁺CD56⁻ (black line), CD3⁺CD56⁺ (blue line), NK (magenta line), after a four hour culture in the presence anti-CD3 plus anti-CD28 microbeads (plain line); * $P < 0.05$; **** $P < 0.0001$; (two-tailed t -test).

4.3 Metabolic programs of freshly isolated CD3⁺CD56⁺ T cells

To define the metabolic profile of CD3⁺CD56⁺ subset, flow cytometry sorted human CD3⁺CD56⁺ T, NK and CD3⁺ T cells were cultured for 1 hour alone or in the presence of anti-CD3 plus anti-CD28 microbeads. Glycolysis and mitochondrial respiration were evaluated by measuring the extra cellular acidification rate (ECAR) and oxygen-consumption rate (OCR), respectively. Unstimulated CD3⁺CD56⁺ cells showed similar rate of basal and maximal glycolysis compared with CD3⁺ T and NK cells. In addition, CD3⁺CD56⁺ evidenced a significant higher glycolytic capacity than NK cells (**Fig. 3a, upper left panels**). TCR stimulation of CD3⁺CD56⁺ cells, similarly to NK, did not increase their basal and maximal glycolysis (**Fig. 3a, upper right panels**). Conversely, the analysis of OCR revealed that unstimulated CD3⁺CD56⁺ T subset had higher basal, ATP-linked and maximal respiration compared to CD3⁺ T cells; maximal respiration was similar to that observed in NK cells (**Fig. 3b, lower left panels**). Upon TCR stimulation CD3⁺CD56⁺ cells showed higher basal, ATP-linked and maximal respiration compared to CD3⁺ T lymphocytes and NK cells (**Fig. 3b, lower right panels**).

These data suggested that CD3⁺CD56⁺ T cells preferentially engage mitochondrial respiration as cellular bio-energetic pathway after TCR triggering.




Fig. 3 Metabolic profiles of CD3⁺, CD3⁺CD56⁺ and NK cell subsets in the presence or absence of stimulation with anti-CD3 plus anti-CD28 microbeads. **(a)** Upper left panels indicate glycolytic profile of flow sorted CD3⁺ (black squares), CD3⁺CD56⁺ (blue squares) and NK (magenta squares) subsets cultured in the presence of Medium or with anti-CD3 plus anti-CD28 microbeads, while the upper right panels show basal, maximal glycolysis and the glycolytic capacity. Mean \pm S.E.M. **(b)** Lower left panels indicate oxygen-consumption rate (OCR) profile of flow sorted CD3⁺ (black squares), CD3⁺CD56⁺ (blue squares) and CD56⁺CD3⁻ (magenta squares) subsets cultured in the presence of Medium or with anti-CD3 plus anti-CD28 microbeads, lower right panels show basal, ATP-linked and maximal respiration. (two-tailed *t*-test) Mean \pm S.E.M.

4.4 CD3⁺CD56⁺ cells modulate TCR-dependent cytotoxicity and the production of IFN- γ in CD8⁺ T cells

To explore the possibility that human CD3⁺CD56⁺ cells contribute to immune regulatory networks, we investigated the capability of this subset to modulate the cytotoxic activity and the IFN- γ production of TCR triggered IL-2PBMC. As shown, IL-2PBMC were stimulated for 4 hours with anti-CD3 plus anti-CD28 microbeads in the presence of autologous freshly isolated CD3⁺CD56⁺, NK or CD3⁺CD8⁺ T cells. To specifically analyze IL-2PBMC, these cells were labeled before co-culture with anti-CD45 mAb. We observed that CD3⁺CD56⁺ lymphocytes significantly impaired both the expression of CD107a/LAMP-1 and IFN- γ production of CD45-labelled CD8⁺CD3⁺ cells gated on IL-2PBMC (**Fig. 4a**). These effects were maintained up to a 0.2:1 CD3⁺CD56⁺/IL-2PBMCs ratio (**data not shown**). As control, the NK or CD3⁺CD8⁺ T cells were not able to modulate CD107a/LAMP-1 expression and IFN- γ production (**Fig. 4a**). In addition, CD3⁺CD56⁺ T cells were unable to significantly modulate CD107a/LAMP-1 expression and IFN- γ production in TCR activated CD3⁺CD4⁺ cells (**data not shown**). We next, investigated whether CD3⁺CD56⁺ lymphocytes exert their regulatory activity also in allogeneic condition. We found that CD3⁺CD56⁺ subset modulated CD107a/LAMP-1 expression and IFN- γ production also when co-cultured with allogeneic CD8⁺CD3⁺ IL-2PBMC stimulated for four hours with anti CD3 plus anti CD28 microbeads (**Fig. 4b**). Conversely, no significant effects on CD107a/LAMP expression and IFN- γ production were observed when allogeneic NK effectors were co-cultured with TCR triggered CD8⁺CD3⁺ IL-2PBMC cells (**data not shown**).

To confirm the regulatory activity of human CD3⁺CD56⁺ cells on isolated CD8⁺ T cells, we cultured flow cytometry sorted CD8⁺CD3⁺ lymphocytes with rhIL-2 (100UI/ml), for 48 hours to obtain purified and sorted IL-2CD8⁺ cells. We found that, also in these experimental conditions, freshly isolated human CD3⁺CD56⁺ cells strongly suppress TCR dependent CD107a/LAMP-1 expression and IFN- γ production of purified IL-2CD8⁺ compared to CD3⁻CD56⁺ (NK) and CD3⁺CD8⁺ T cells as controls (**Fig. 5**). Together these data indicated that human CD3⁺CD56⁺ cells exert regulatory activity on TCR-dependent cytotoxic activity of CD8⁺ T cells.

Then, we evaluated the ability of CD3⁺CD56⁺ cells to affect the proliferation of CD4⁺ and CD8⁺ T lymphocytes stimulated with anti-CD3 plus anti-CD28 microbeads *in vitro*. We observed that flow cytometry sorted CD3⁺CD56⁺ cells reduced [³H] thymidine incorporation CD3⁺CD8⁺ purified cells and have not significant effect on proliferation of cytometry sorted CD3⁺CD4⁺ (**Fig. 6**). In addition, cell division was assessed by CFSE staining, confirming an inhibition on the CD3⁺CD8⁺ cells as compared with the CD3⁺CD4⁺ counterpart (**data not shown**).

Finally, to investigate whether CD3⁺CD56⁺ cells maintain their phenotype and regulatory properties overtime, we generated short-term cell lines culturing freshly isolated CD3⁺CD56⁺ cells in the presence of anti-CD3 plus anti-CD28 microbeads for 10 days with regular supplementation of hrIL-2. We observed that from 8 to 10% of cultured CD3⁺CD56⁻ cells acquired CD56 molecule expression. Intriguingly, such induced CD3⁺CD56⁺ maintain their ability to suppress CD107a/LAMP-1 expression of IL-2CD8⁺ (**Fig. 7**).

Taken together, these data indicate that CD3⁺ CD56⁺ co-expression identifies a plastic human T cell subset regulating the effector functions of TCR activated CD8⁺ T cells.




Fig. 4 Upper and lower panels show CD107a/LAMP-1 and IFN- γ staining profiles of flow cytometry gated CD8⁺ IL2-PBMC T cells after a 4 hours culture with anti-CD3 plus anti-CD28 microbeads; **(a)** Upper panels show CD107a/LAMP-1 and IFN- γ staining of flow cytometry gated CD8⁺ T cells after a 4 hour culture of IL2-PBMC stimulated with anti-CD3 plus anti-CD28 microbeads; IL2-PBMC (black line) and co-cultures with CD3⁺CD56⁺ (blue line), CD3⁻CD56⁺ (magenta line), CD3⁺CD8⁺ cells (green line) are shown; dotted lines indicate medium culture. **(b)** Lower panels indicate that CD3⁺CD56⁺ lymphocytes exert their regulatory activity both in autologous or allogeneic conditions. IL2PBMC (black line) and co-cultures with CD3⁺CD56⁺ (blue line) are shown.




Fig. 5 Regulatory activity of CD3⁺CD56⁺ cells on sorted purified IL2-CD8⁺CD3⁺ cells. This panels show CD107a/LAMP-1 and IFN- γ staining profiles of IL2-CD8⁺ sorted cells after a 4 hour stimulation with anti-CD3 plus anti-CD28 microbeads; data are from one of three independent experiments; IL2-CD8 (black line) and co-cultures with CD3⁺CD56⁺ (blue line), CD3⁻CD56⁺ (magenta line) and CD3⁻CD8⁺ cells (green line) are shown; dotted lines indicate medium culture.




Fig. 6 CD3⁺CD56⁺ lymphocytes suppress proliferation of TCR activated CD8⁺ T cells. **(a)** Left panels show thymidine incorporation of flow cytometry sorted CD8⁺ T lymphocytes cultured for 72 hours with anti-CD3 plus anti-CD28 microbeads, alone (green column) or in the presence of CD3⁺CD56⁺ cells at the indicated different ratios (blue columns) Mean \pm S.E.M. **(b)** Right panels show thymidine incorporation of flow cytometry sorted CD4⁺ T lymphocytes cultured for 72 hours with anti-CD3 plus anti-CD28 microbeads alone (orange column) or in the presence of CD3⁺CD56⁺ cells at the indicated ratios (blue columns). Cell proliferation was evaluated as ³H thymidine incorporation in the last 6 hours Left and Right panels indicate results obtained in eight independent experiments (n=8). Mean \pm S.E.M. * $P < 0.05$; (two-tailed Mann Whitney test).




Fig. 7 Freshly isolated, sorted CD3⁺CD56⁻ cells (purity >99%) were cultured for 10 days in the presence of anti-CD3 plus anti-CD28 microbeads and regular rhIL-2 supplementation (upper left and right panels respectively). As shown, after 10 days culture; these “induced” CD3⁺CD56⁺ cells were isolated and co-cultured with TCR activated IL2-CD8⁺. Low panels show CD107a/LAMP-1 expression by IL2-CD8⁺ stimulated for 4 hours with anti-CD3 plus anti-CD28 microbeads alone (left lower panel) or in the presence of “induced” CD3⁺CD56⁺ (right lower panel). Data are from one representative experiment.

4.5 CD3⁺CD56⁺ regulatory activity requires cell to cell contact and is independent on CD56-mediated interactions

In order to investigate on the mechanisms underlying CD3⁺CD56⁺ regulatory properties, we first evaluated whether suppressive activity of CD3⁺CD56⁺ cells relied on direct cell-cell contact with TCR target cells or depends on soluble molecules. As shown CD3⁺CD56⁺ cells lost their suppressive capacity when physical separated from CD8⁺ cells in a transwell assay. This results were obtained when anti-CD3 plus anti-CD28 microbeads were added to IL-2CD8⁺ cells (low chamber) or to both IL-2CD8⁺ and CD3⁺CD56⁺ cells (low and upper chambers) (**Fig. 8**). To investigate the direct involvement of CD56 in delivering contact-dependent suppressive signals, either CD3⁺CD56⁺ and IL-2CD8⁺ cells were cultured with saturating concentration of soluble human recombinant neural cell adhesion molecule (hrNCAM/CD56) or anti-CD56 mAb, (30min) and successively they were tested for their ability to suppress activity of TCR stimulated IL-2CD8⁺ T. We found that in these experimental conditions, CD3⁺CD56⁺ lymphocytes retained their capability to modulate effector functions of TCR activated CD8⁺ IL-2PBMc in term of CD107a/LAMP-1 expression and IFN- γ production by TCR activated IL-2CD8 cells. Some results were obtained when CD3⁺CD56⁺ lymphocytes were pre-treated with hrNCAM/CD56 or anti-CD56 mAbs before culture. Thus, CD56 dependent contact was not relevant for CD3⁺CD56⁺ regulatory activity (**Fig. 9**).




Fig. 8 CD3⁺CD56⁺ regulatory functions require cell to cell contact. This panel indicates CD107a/LAMP-1 and IFN- γ staining of IL-2CD8⁺ after a 4 hour culture with anti-CD3 plus anti-CD28 microbeads; IL-2CD8⁺ (black line) or co-cultures with CD3⁺CD56⁺ cells (blue line) are shown; as indicated, CD3⁺CD56⁺ co-cultures were performed using transwell device in order to prevent cell to cell contact. These results were obtained when anti-CD3 plus anti-CD28 microbeads were added to IL-2CD8⁺ cells (low chamber) or to both IL-2CD8⁺ and CD3⁺CD56⁺ cells (low and upper chambers).




Fig. 9 CD3⁺CD56⁺ regulatory functions do not involve CD56-dependent interactions. CD107a/LAMP-1 staining of IL2-CD8⁺ after a 4hour culture with anti-CD3 plus anti-CD28 microbeads; IL2-CD8⁺ (black line) or co-cultures with CD3⁺CD56⁺ cells (blue line) are shown; as indicated, CD3⁺CD56⁺ co-cultures were performed in the presence of anti-CD56 mAb, NCAM/CD56 recombinant molecule and the control 345.134 IgG2a mAb; data are from one representative experiment out of three.

4.6 T1D subjects show a reduced number and impaired suppressive activity of CD3⁺CD56⁺ cells

Previously data from our laboratory have showed that circulating CD3⁺CD56⁺ cell number correlate with β -cell residual function up to one year after diabetes diagnosis. In fact, high number of CD3⁺CD56⁺ cells directly correlated with pancreatic β -cell activity one year after diagnosis³⁹. In this study we analyzed both number and suppressive capability of CD3⁺CD56⁺ cells in a large cohort of T1D affected children at disease onset, in comparison with age- and sex-matched healthy subjects. We found that, at diagnosis, both percentage and absolute number of this cell subset were significantly lower in T1D children (n=100) than healthy subjects (n=70) (**Fig. 10 a, b**). To better understanding the role of CD3⁺CD56⁺ cells in the pathogenesis of T1D, we tested the ability of flow sorted CD3⁺CD56⁺ lymphocytes from T1D individuals to modulate TCR dependent CD107a of autologous CD8⁺ cells gate on IL-2PBMC.

As shown, CD3⁺CD56⁺ cells from T1D subjects (n=13) had impaired suppressive ability to modulate CD107a expression when co-cultured with TCR engaged CD8⁺ IL-2PBMC, cells compared with age and sex-matched healthy individuals (n=17) (**Fig. 10c**). Moreover, to discriminate whether impaired suppression observed in CD3⁺CD56⁺ from T1D subjects may be ascribed to resistance of their CD8⁺ T cells, we co-cultured healthy donor CD3⁺CD56⁺ cells with T1D-derived IL-2PBMC lymphocytes. CD3⁺CD56⁺ cells from healthy subjects suppressed cytotoxic activity of IL-2PBMC cells from T1D subjects; however, autologous CD3⁺CD56⁺ cells showed impaired suppressive capability (**data not shown**).

These findings indicated a specific defect in numbers and function of human CD3⁺CD56⁺ cell compartment in autoimmune diabetes.




Fig. 10 T1D children at diagnosis show a reduced percentage and absolute number and impaired suppressive activity of CD3⁺CD56⁺ cells. (a and b). Left and right upper panels indicate respectively the percentage and absolute number of peripheral CD3⁺CD56⁺ lymphocytes in T1D children (n=100) at disease onset, as compared with age/sex matched healthy controls (n=70); (c) Cumulative data of CD107a/LAMP-1 inhibition by CD3⁺CD56⁺ cells, staining of CD8⁺ gated IL2-PBMC, from T1D compared (n=13), to healthy donors, (n=17); * $P < 0.0005$; ** $P < 0.0001$; (two-tailed Mann Whitney test).

4.7 Subjects with prostate cancer show a higher number of CD3⁺CD56⁺ cells in peripheral blood.

Subjects with prostate cancer show a higher number of CD3⁺CD56⁺ cells in peripheral blood (n=10) compared to normal blood collected from healthy individuals (n=12). PBMCs were isolated using Ficoll-Paque density gradient centrifugation, from subjects with prostate cancer. The cell suspension was then used for flow cytometry analysis (Fig. 11a). Furthermore, the percentage of CD3⁺CD56⁺ T lymphocytes in the peripheral blood of patients with prostate cancer positive correlation with the Gleason grades (Fig. 11b).




Fig. 11. a) frequency of CD3⁺CD56⁺ lymphocytes in peripheral blood of prostate cancer patients (n=10), compared with age/sex matched healthy controls (n=12); b) CD3⁺CD56⁺ T lymphocytes in the peripheral blood of patients with prostate cancer positively correlates with the Gleason grades, (GS). Mean ± S.E.M. * $P < 0.05$; ** $P < 0.01$ (two-tailed Mann Whitney test).

5. DISCUSSION AND CONCLUSION

This study reveals that CD3⁺CD56⁺ co-expression identifies a T cell subset with previously unexplored regulatory properties able to modulate TCR-dependent effector functions of human CD8⁺ T cells. Here we found that human freshly isolated CD3⁺CD56⁺ cells suppress cytotoxicity and IFN- γ production of *in vitro* activated CD8⁺ T lymphocytes in both autologous and allogeneic conditions. Decreased number and impairment of suppressive activity of CD3⁺CD56⁺ cells were observed in a large cohort of children affected by autoimmune diabetes. This strongly suggests the involvement of CD3⁺CD56⁺ cells in control of immune tolerance and in the development of autoimmune condition.

Human CD3⁺CD56⁺ cells represent a distinct T cell subset preferentially expressing CD8 co-receptor with a heterogeneous $\alpha\beta$ -TCR repertoire, clearly divergent from NKT, as testified by the lack of binding with CD1d tetramer and the absence of TCR-V α 24/V β 11 chains. CD3⁺CD56⁺ cells up-regulate cytotoxic molecules, produce IFN- γ and display a low proliferative rate upon TCR stimulation *in vitro*; they are unresponsive to NK-dependent stimuli, in terms of cytotoxicity and cytokine production. A specific metabolic signature, engaging the mitochondrial respiration rather than glycolysis upon TCR activation, characterizes this cell subset.

Freshly isolated human CD3⁺CD56⁺ cells specifically suppress cytotoxicity and IFN- γ production of co-cultured human CD8⁺ T cells *in vitro*. These modulating effects are exerted in both autologous and allogeneic conditions. We also show that CD3⁺CD56⁺ cells affect TCR-dependent proliferation of CD8⁺ but have not significant effect on proliferation CD4⁺ subsets. Overall this data suggest that CD3⁺CD56⁺ cells represent a T cell subset with specific phenotypic profile, functional properties and metabolic requirements. These data are in line with previous evidences suggesting a possible regulatory role of this population^{34-36,100}. These findings are also in agreement with observations found by our laboratory showing that absolute numbers of CD3⁺CD56⁺ circulating cells associate with higher residual β -cell function in subjects affected by T1D³⁹.

CD3⁺CD56⁺ cells represent a plastic regulatory T cell subset. Indeed, in our experimental system TCR stimulation (in the presence of low doses of hrIL-2) of CD3⁺CD56⁻ cells gave rise to a fraction of "induced" CD3⁺CD56⁺ cells able to

suppress effector functions of CD8⁺ T cells activated *via* TCR. These reflect the behavior of well-characterized induced Foxp3⁺ Treg (iTreg) cells¹⁰¹⁻¹⁰². However, suppressive capability of CD3⁺CD56⁺ cells is not related to the expression of common regulatory cell lineage markers, such as Foxp3, CTLA-4, GITR and CD49d.

Furthermore, regulatory ability of CD3⁺CD56⁺ cells strictly relied on cell-to-cell contact and is independent on CD56-mediated interactions^{8,103-105}. However, the precise mechanism and surface molecules mediating this suppressive function remain to be explored.

Apoptosis induction has been reported to represent a key regulatory mechanism required to maintain immune homeostasis¹⁰⁶⁻¹⁰⁷. In our experimental conditions, we found that apoptosis was dispensable for regulatory activity of human CD3⁺CD56⁺ subset. Indeed, CD3⁺CD56⁺ lymphocytes significantly suppress CD107a/LAMP-1 expression and IFN- γ production of TCR activated non apoptotic (Annexin V negative) CD8⁺ T cells.

There is growing evidence showing the key role of CD8⁺ T cells in the pathogenesis of several autoimmune disorders including multiple sclerosis (MS) and T1D¹⁰⁸⁻¹¹¹. Here we report that in a large cohort T1D child, at diagnosis, CD3⁺CD56⁺ cells were reduced in comparison with healthy individuals and that fail to suppress CD8⁺ effector functions *in vitro*. These data extend our previous observation showing that CD3⁺CD56⁺ cell number at diagnosis predicts residual β -cell function in T1D one year later³⁹. Remarkably, our results are conceivable with the hypothesis that altered CD3⁺CD56⁺ number and function may account for the deranged effector function of CD8⁺ T lymphocytes, typical of T1D¹⁰⁹⁻¹¹¹.

The study of the role of host immune system in the tumour microenvironment is crucial for understanding how they affect the development and course of human tumors¹¹²⁻¹¹³. In the present study, we investigated the involvement of CD3⁺CD56⁺ cells in the pathogenesis of prostate cancer. Here we observed that CD3⁺CD56⁺ cells were higher in prostate cancer patients and directly correlated with Gleason grade, indicating that activity of CD3⁺ CD56⁺ cells could be involved in prostatic tumours progression.

In summary, human CD3⁺CD56⁺ cells represent a plastic T cell subset, involved in the control of CD8⁺mediated immune response. Dysregulation in regulatory

functions of this cell subset could determine an altered immune response, that lead to disorder such as T1D and cancer. Obtained result may pave the way to new experimental approaches aimed to expand CD3⁺CD56⁺ cells in vitro that may reshape CD8⁺ T cell hyper-activation in autoimmunity. Conversely, targeting of this regulatory cell subset in human cancer could help improve anti-cancer immune response during tumor progression. In perspective, the therapeutic manipulation of CD3⁺CD56⁺ and their monitoring may represent a novel target for immune interventions upon alteration of immune response.

6. ACKNOWLEDGMENTS

I would like to express my sincere gratitude to Dr. Mario Galgani, for giving me the opportunity to make this fascinating experience during my entire doctorate, and for conveying to me the profound passion for research.

In particular, I would like to thank my Tutor Prof. ssa Donatella Tramontano, for helping me in all the time of my research experience.

My special thanks go to Prof. Giuseppe Matarese, who gave me the opportunity to work with him and his research team in the "Laboratory of Immunology, at Department of Molecular Medicine e Medical Biotechnology, University of Naples Federico II". He supported me throughout my PhD course and made this period of my life productive and stimulating. I also would like to thank my laboratory colleagues. They all have contributed to my personal and professional growth, and have been a source of friendships as well as good advice and collaboration.

7. REFERENCES

1. Nurieva R.I., Liu X. & Dong C. Molecular mechanisms of T-cell tolerance. *Immunol Rev* **241**:133-144. (2011).
2. Schreiber R.D., Old L.J., & Smyth M.J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. *Science* **331**:1565-1570. (2011)
3. Medzhitov R., Schneider D.S. & Soares M.P. Disease tolerance as a defense strategy. *Science* **335**:936-941 (2012).
4. Schneider D.S. & Ayres J.S. Two ways to survive infection: what resistance and tolerance can teach us about treating infectious diseases. *Nat Rev Immunol* **8**:889-895 (2008).
5. Senovilla L., Galluzzi L., Zitvogel L. & Kroemer G. Immunosurveillance as a regulator of tissue homeostasis. *Trends Immunol* **34**:471-481 (2013).
6. Allan S.E. et al. CD4+ T-regulatory cells: toward therapy for human diseases. *Immunol Rev* **223**:391-421 (2008).
7. Carrier Y., Yuan J., Kuchroo V.K. & Weiner H.L. Th3 cells in peripheral tolerance. I. Induction of Foxp3-positive regulatory T cells by Th3 cells derived from TGF-beta T cell-transgenic mice. *J Immunol* **178**:179-185 (2007).
8. Rudensky A.Y. Regulatory T cells and Foxp3. *Immunol Rev* **241**:260-268 (2011).
9. Ohkura N., Kitagawa Y. & Sakaguchi S. Development and maintenance of regulatory T cells. *Immunity* **38**:414-423 (2013).
10. Lu L. & Cantor H. Generation and regulation of CD8(+) regulatory T cells. *Cell Mol Immunol* **5**:401-406 (2008).
11. Colovai A.I. et al. Induction of xenoreactive CD4+ T-cell anergy by suppressor CD8+CD28- T cells. *Transplantation* **69**:1304-1310 (2000).
12. Joosten S.A. & Ottenhoff T.H. Human CD4 and CD8 regulatory T cells in infectious diseases and vaccination. *Hum Immunol* **69**:760-770 (2008).
13. Pomie C., Menager-Marcq I. & van Meerwijk J.P.M. Murine CD8+ regulatory T lymphocytes: the new era. *Hum Immunol* **69**:708-714 (2008).
14. Tsai S., Clemente-Casares X. & Santamaria P. CD8(+) Tregs in autoimmunity: learning "self"-control from experience. *Cell Mol Life Sci* **68**:378137-95 (2011).
15. Wang R.F. CD8+ regulatory T cells, their suppressive mechanisms, and regulation in cancer. *Hum Immunol* **69**:811-814 (2008).
16. Liu Z., Tugulea S., Cortesini R. & Suci-Foca N. Specific suppression of T helper alloreactivity by allo-MHC class I-restricted CD8+CD28- T cells. *Int Immunol* **10**:775-783 (1998).
17. Varthaman A. et al. Control of T cell reactivation by regulatory Qa-1-restricted CD8+ T cells. *J Immunol* **184**:6585-6591 (2010).
18. Koch S.D., Uss E., van Lier R.A. & ten Berge I.J. Alloantigen-induced regulatory CD8+CD103+ T cells. *Hum Immunol* **69**:737-744 (2008).

19. Hu D., Liu X., Zeng W., Weiner H.L. & Ritz J. A clonal model for human CD8+ regulatory T cells: unrestricted contact-dependent killing of activated CD4+ T cells. *Eur J Immunol* **42**: 69-79 (2012).
20. Cosmi L., et al. Human CD8+CD25+ thymocytes share phenotypic and functional features with CD4+CD25+ regulatory thymocytes. *Blood* **102**:4107–4114 (2003).
21. Mahic M. et al. Generation of highly suppressive adaptive CD8+CD25+FOXP3+ regulatory T cells by continuous antigen stimulation. *Eur J Immunol* **38**:640–646 (2008).
22. Demers K.R., Reuter M.A. & Betts M.R. CD8(+) T-cell effector function and transcriptional regulation during HIV pathogenesis. *Immunol Rev.* **254**:190-206 (2013).
23. Segnin, M.C., Klotz F.W., Schneider I., Weir J.P., Goodbary M., Slayter M., Raney J.J., Aniagolu J.U., and Green S.J. Induction of nitric oxide synthase protects against malaria in mice exposed to irradiated Plasmodium berghei-infected mosquitoes: involvement of interferon γ and CD8 + T cells. *J. Exp. Med.* **180**:353—358 (1994).
24. Rifa'i M., Kawamoto Y., Nakashima I. & Suzuki H. Essential roles of CD8+CD122+ regulatory T cells in the maintenance of T cell homeostasis. *J Exp Med* **200**:1123-1134 (2004).
25. Nishikawa H. & Sakaguchi S. Regulatory T cells in cancer immunotherapy. *Curr Opin Immunol* **27**:1-7 (2014).
26. Beyer M. & Schultze J.L. Regulatory T cells in cancer. *Blood* **108**:804–811 (2006).
27. Bates G.J. et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. *J Clin Oncol* **24**:5373-5380 (2006).
28. Curiel T.J. et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. *Nat Med* Sep **10**:942-949 (2004).
29. Sato E. et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. *Proc Natl Acad Sci U S A* **102**:18538-18543 (2005).
30. Zhang S. et al. Analysis of CD8+ Treg cells in patients with ovarian cancer: a possible mechanism for immune impairment. *Cell Mol Immunol* **12**:580-591 (2015).
31. Kuniwa Y. et al. CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer. *Clin Cancer Res* **13**:6947-6958 (2007).
32. Schmidt R.E., Murray C., Daley J.F., Schlossman S.F. & Ritz J. A subset of natural killer cells in peripheral blood displays a mature T cell phenotype. *J Exp Med* **164**:351-356 (1986).

33. Werner J.M. et al. Distribution of intrahepatic T, NK and CD3(+)/CD56(+)/NKT cells alters after liver transplantation: Shift from innate to adaptive immunity?. *Transpl Immunol* **25**:27-33 (2011).
34. Zhou J. et al. High circulating CD3+CD56+CD16+ natural killer-like T cell levels predict a better IVF treatment outcome. *J Reprod Immunol* **97**:197-203 (2013).
35. Diao H. et al. A possible role for NKT-like cells in patients with chronic hepatitis B during telbivudine treatment. *Immunol Lett* **160**:65-71 (2014).
36. Das R. & Tripathy A. Increased expressions of NKp44, NKp46 on NK/NKT-like cells are associated with impaired cytolytic function in self-limiting hepatitis E infection. *Med Microbiol Immunol* **203**:303-314 (2014).
37. Pang Y.L. et al. The immunosuppressive tumor microenvironment in hepatocellular carcinoma. *Cancer Immunol Immunother* **58**:877-86 (2009).
38. Bamias A. et al. Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy. *Gynecol Oncol* **108**:421-427 (2008).
39. Galgani M. et al. Meta-immunological profiling of children with type 1 diabetes identifies new biomarkers to monitor disease progression. *Diabetes* **62**:2481-2491 (2013)
40. Hu D., Weiner H.L. & Ritz J. Identification of cytolytic CD161- CD56+ regulatory CD8 T cells in human peripheral blood. *PLoS One* **8**:e59545 (2013).
41. Erlich H. et al. HLA DR-DQ haplotypes and genotypes and type 1 diabetes risk: analysis of the type 1 diabetes genetics consortium families. *Diabetes* **57**:1084–1092 (2008).
42. Gillespie K.M. Type 1 diabetes: pathogenesis and prevention. *CMAJ* **175**:165-170 (2006).
43. Eisenbarth G.S. & Gottlieb P.A. Autoimmune polyendocrine syndromes. *N Engl J Med* **350**:2068-2067 (2004).
44. Todd J.A. Etiology of type 1 diabetes. *Immunity* **32**:457-467 (2010).
45. Concannon P., Rich S.S. & Nepom G.T. Genetics of type 1A diabetes. *N Engl J Med* **360**: 1646–1654 (2009).
46. Knip M. et al. Humoral beta-cell autoimmunity in relation to HLA-defined disease susceptibility in preclinical and clinical T1D. *Am J Med Genet* **115**:48-54 (2002).
47. Steck A.K. et al. Predictors of Progression From the Appearance of Islet Autoantibodies to Early Childhood Diabetes: The Environmental Determinants of Diabetes in the You (TEDDY). *Diabetes Care* **38**:808-813 (2015).
48. Sherr J., Sosenko J., Skyler J. & Herold K. Prevention of type 1 diabetes: the time has come. *Nat Clin Pract Endocrinol Metab* **4**:334–343 (2008).

49. Atkinson M.A. The pathogenesis and natural history of type 1 diabetes. *ColdSpring Harb Perspect Med* **2** (2012).
50. Yu L. et al. Expression of GAD65 and islet cell antibody (ICA512) autoantibodies among cytoplasmic ICA+ relatives is associated with eligibility for the Diabetes Prevention Trial-Type 1. *Diabetes* **50**:1735–1740 (2001).
51. Wenzlau J.M. et al. Novel antigens in type 1n diabetes: the importance of ZnT8. *Curr Diab Rep* **9**:105–112 (2009)
52. Achenbach P., Bonifacio E., Koczwara K. & Ziegler A.G. Natural history of type 1 diabetes. *Diabetes* **54 Suppl2**:S25-31 (2005).
53. Yeung W.C, Rawlinson W.D & Craig M.E. Enterovirus infection and type 1 diabetes mellitus: systematic review and meta-analysis of observational molecular studies. *BMJ* **342**:d35 (2011).
54. Atkinson M.A., et al. Cellular immunity to a determinant common to glutamate decarboxylase and coxsackie virus in insulin-dependent diabetes. *J Clin Invest* **94**:2125-2129 (1994).
55. Dotta F. et al. Coxsackie B4 virus infection of beta cells and natural killer cell insulinitis in recent-onset type 1 diabetic patients. *Proc Natl Acad Sci U S A* **104**:5115-5120 (2007).
56. Yoon J.W., Austin M., Onodera T. & Notkins A.L. Isolation of a virus from the pancreas of a child with diabetic ketoacidosis. *N Engl J Med* **300**:1173-1179 (1979).
57. Anagandula M. et al. Infection of human islets of Langerhans with two strains of coxsackie B virus serotype 1: assessment of virus replication, degree of cell death and induction of genes involved in the innate immunity pathway. *J Med Virol* **86**:1402–1411 (2014).
58. Szopa T.M., Gamble D.R. & Taylor K.W. Coxsackie B4 virus induces short-term changes in the metabolic functions of mouse pancreatic islets in vitro. *Cell Biochem Funct.* **4**:181-7 (1986).
59. Dotta F. et al. Coxsackie B4 virus infection of beta cells and natural killer cellinsulinitis in recent-onset type 1 diabetic patients. *Proc Natl Acad Sci USA* **104**:5115-20 (2007).
60. Jaïdane H. & Hober D. Role of coxsackievirus B4 in the pathogenesis of type diabetes. *Diabetes Metab.* **34**:537-48 (2008).
61. Jaïdane H. et al. Coxsackievirus B4 and type 1 diabetes pathogenesis: contribution of animal models. *Diabetes Metab Res Rev.* **25**:591-603 (2009).
62. Belkaid Y. & Hand T.W. Role of the microbiota in immunity and inflammation. *Cell* **157**:121-41 (2014).
63. Sarikonda G. et al. CD8 T-cell reactivity to islet antigens is unique to type 1 while CD4 T-cell reactivity exists in both type 1 and type 2 diabetes. *J Autoimmun* **50**:77-82 (2014).
64. Willcox A., Richardson S.J., Bone A.J., Foulis A.K. & Morgan N.G. Analysis of islet inflammation in human type 1 diabetes. *Clin Exp Immunol* **155**:173-181 (2009).

65. Skowera A. et al. β -cell-specific CD8 T cell phenotype in type 1 diabetes reflects chronic autoantigen exposure. *Diabetes* **64**:916-925 (2015).
66. Rodriguez-Calvo T., Ekwall O., Amirian N., Zapardiel-Gonzalo J. & von Herrath MG. Increased immune cell infiltration of the exocrine pancreas: a possible contribution to the pathogenesis of type 1 diabetes. *Diabetes* **63**:3880-3890 (2014).
67. Santamaria P. The long and winding road to understanding and conquering type 1 diabetes. *Immunity* **32**:437-445 (2010).
68. Simoni Y., Diana J., Ghazarian L., Beaudoin L. & Lehuen A. Therapeutic manipulation of natural killer (NK) T cells in autoimmunity: are we close to reality? *Clin Exp Immunol* **171**:8-19 (2013).
69. Rodacki M., Milech A. & de Oliveira J.E. NK cells and type 1 diabetes. *Clin Dev Immunol* **13**:101-107 (2006).
70. Lehuen A., Diana J., Zacccone P. & Cooke A. Immune cell crosstalk in type 1 diabetes. *Nat Rev Immunol* **10**:501-513 (2010).
71. Alleva D.G., Pavlovich R.P., Grant C., Kaser S.B. & Beller D.I. Aberrant macrophage cytokine production is a conserved feature among autoimmune-prone mouse strains: elevated interleukin (IL)-12 and an imbalance in tumor necrosis factor- α and IL-10 define a unique cytokine profile in macrophages from young nonobese diabetic mice. *Diabetes* **49**:1106–1115 (2000).
72. Jun H.S., Yoon C.S., Zbytnuik L., van Rooijen N. & Yoon J.W. The role of macrophages in walkerT cell-mediated autoimmune diabetes in nonobese diabetic mice. *J Exp Med* **189**:347–358 (1999).
73. Cantor J. & Haskins K. Recruitment and activation of macrophages by pathogenic CD4 T cells in type 1 diabetes: evidence for involvement of CCR8 and CCL1. *J Immunol* **179**:5760-7 (2007).
74. Stadinski B., Kappler J. & Eisenbarth G.S. Molecular targeting of islet autoantigens. *Immunity* **32**:446-456 (2010).
75. Silveira P.A & Grey S.T. B cells in the spotlight: innocent bystanders or major players in the pathogenesis of type 1 diabetes. *Trends Endocrinol Metab* **17**:128–135 (2006).
76. Pakala S.V., Chivetta M., Kelly C.B. & Katz J.D. In autoimmune diabetes the transition from benign to pernicious insulinitis requires an islet cell response to tumor necrosis factor alpha. *J Exp Med* **189**:1053–1062 (1999).
77. Sutherland A.P. et al. Interleukin-21 is required for the development of type 1 diabetes in NOD mice. *Diabetes* **58**:1144–1155 (2009).
78. Brodie G.M., Wallberg, M., Santamaria P., Wong, F.S. & Green, E.A. B-cells promote intra-islet CD8+ cytotoxic T-cell survival to enhance type 1 diabetes. *Diabetes* **57**:909–917 (2008).
79. Hulbert C., Riseili, B., Rojas, M., & Thomas, J.W. B cell specificity contributes to the outcome of diabetes in nonobese diabetic mice. *J Immunol* **167**:5535–5538 (2001).
80. Alba A. et al. Natural killer cells are required for accelerated type 1 diabetes driven by interferon-beta. *Clin Exp Immunol*. Mar; **151**(3):467-75. 2008.

81. Meka R.R., Venkatesha S.H., Dudics S., Acharya B. & Moudgil K.D. IL-27-induced modulation of autoimmunity and its therapeutic potential. *Autoimmun Rev* **14**:1131-1141 (2015).
82. Vetere A., Choudhary A., Burns S.M., & Wagner B.K. Targeting the pancreatic β -cell to treat diabetes. *Nat Rev Drug Discov* **13**:278-289 (2014).
83. Sarvetnick N. et al. Loss of pancreatic islet tolerance induced by beta-cell expression of interferon-gamma. *Nature* **346**:844-847 (1990).
84. Mathis D., Vence, L., & Benoist C. beta-Cell death during progression to diabetes. *Nature* **414**:792-798 (2001).
85. Wachlin G. et al. IL-1beta, IFN-gamma and TNF-alpha increase vulnerability of pancreatic beta cells to autoimmune destruction. *J Autoimmun* **20**:303-312 (2003).
86. Harty J.T., & Bevan M.J. Responses of CD8(+) T cells to intracellular bacteria. *Curr Opin Immunol* **11**:89-93 (1999)
87. Sutherland A.P. et al. IL-21 promotes CD8+ CTL activity via the transcription factor T-bet. *J Immunol* **190**:3977-3984 (2013).
88. Rasche S., Busick R.Y., & Quinn A. GAD65- Specific Cytotoxic T lymphocytes mediate beta-cell death and loss of function. *Rev Diabet Stud* **6**:43-53 (2009).
89. Bulek A.M. et al. Structural basis for the killing of human beta cells by CD8(+) T cells in type 1 diabetes. *Nat Immunol* **13**:283-289 (2012).
90. Clarke S. The critical role of CD40 CD40L in the CD4-dependent generation of CD8(+) T cell immunity. *J Leukocyte Biol* **67**:607-614 (2000).
91. Ghazarian L. et al. Prevention or acceleration of type 1 diabetes by viruses. *Cell Mol Life Sci* **70**:257 (2013).
92. Fox C.K., Furtwaengler, A., Nepomuceno R.R., Martinez O.M. & Krams S.M. Apoptotic pathways in primary biliary cirrhosis and autoimmune hepatitis. *Liver* **21**:272-279 (2001).
93. Blanco P. et al. Increase in activated CD8+ T lymphocytes expressing perforin and granzyme B correlates with disease activity in patients with systemic lupus erythematosus. *Arthritis Rheum* **52**:201-211 (2005).
94. Malmeström C. et al. Relapses in multiple sclerosis are associated with increased CD8+ T-cell mediated cytotoxicity in CSF. *J Neuroimmunol* **196**:159-165 (2008).
95. Cacciapaglia F. et al. Apoptotic molecular mechanisms implicated in autoimmune diseases. *Eur. Rev. Med. Pharmacol. Sci.* **13** :23-40 (2009)
96. Procaccini C. et al. An oscillatory switch in mTOR kinase activity sets regulatory T cell responsiveness. *Immunity* **33**:929-941 (2010).
97. Craig M.E., Hattersley A., & Donaghue K.C. Definition, epidemiology and classification of diabetes in children and adolescents. *Pediatr Diabetes* **12**:3-12 (2009).

98. Wood S.M. & Bryceson Y.T. Lymphocytes cytotoxicity: tug-of-war on microtubules. *Blood* **119**:3873-5 (2012).
99. Alter G., Malenfant J.M., & Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. *J Immunol Methods* **294**:15-22. (2004).
100. Chernyshov V.P. et al. Elevated NK cell cytotoxicity, CD158a expression in NK cells and activated T lymphocytes in peripheral blood of women with IVF failures. *Am J Reprod Immunol* **64**:58-67 (2010).
101. Bilate A.M. & Lafaille J.J. Induced CD4+Foxp3+ regulatory T cells in immune tolerance. *Annu. Rev. Immunol.* **30**:733-58 (2012).
102. De Rosa V. et al. Glycolysis controls the induction of human regulatory T cells by modulating the expression of FOXP3 exon 2 splicing variants. *Nat Immunol* **16**:1174-1184 (2015).
103. Walker L.S. & Sansom D.M. Confusing signals: recent progress in CTLA-4 biology. *Trends Immunol* **36**:63-70 (2015).
104. Kraczyk B., Remus R. & Hardt C. CD49d Treg cells with high suppressive capacity are remarkably less efficient on activated CD45RA- than on naive CD45RA+ Teff cells. *Cell Physiol Biochem* **34**:346-355 (2014).
105. Schneider-Hohendorf T. et al. VLA-4 blockade promotes differential routes into human CNS involving PSGL-1 rolling of T cells and MCAM-adhesion of TH17 cells. *J Exp Med* **211**:1833-1846 (2014).
106. Strasser A., Jost P.J. & Nagata S. The many roles of FAS receptor signaling in the immune system. *Immunity* **30**:180-192 (2009).
107. Akane K., Kojima S., Mak T.W. Shiku H. & Suzuki, H. CD8+CD122+CD49d^{low} regulatory T cells maintain T-cell homeostasis by killing activated T cells via Fas/FasL-mediated cytotoxicity. *Proc Natl Acad Sci U S A* **113**:2460-2465 (2016).
108. Lucchinetti C.F. et al. Inflammatory cortical demyelination in early multiple sclerosis. *N Engl J Med* **365**:2188-2197 (2011).
109. Kägi D. et al. Reduced incidence and delayed onset of diabetes in perforin-deficient non obese diabetic mice. *J Exp Med* **86**:989-997 (1997).
110. Wong C.P. et al. Identical beta cell-specific CD8(+) T cell clonotypes typically reside in both peripheral blood lymphocyte and pancreatic islets. *J Immunol* **178**:1388-1395 (2007).
111. Nejentsev S. et al. Localization of type 1 diabetes susceptibility to the MHC class I genes HLA-B and HLA-A. *Nature* **450**:887-892 (2007).
112. Galon J., Angell H.K., Bedognetti D. & Marincola F.M. The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. *Immunity* **39**:11-26 (2013).
113. Pagès F. et al. Immune infiltration in human tumors: a prognostic factor that should not be ignored. *Oncogene* **29**:1093-1102 (2010).

8. List of publications production during PhD course:

1. Procaccini C, **Santopaolo M**, Faicchia D, Colamatteo A, Formisano L, de Candia P, Galgani M, De Rosa V, Matarese G. Role of metabolism in neurodegenerative disorders. *Metabolism*. 2016 Sep;65(9):1376-90.
2. Guida N, Laudati G, Mascolo L, Cuomo O, Anzilotti S, Sirabella R, **Santopaolo M**, Galgani M, Montuori P, Di Renzo G, Canzoniero LM, Formisano L. MC1568 Inhibits Thimerosal-Induced Apoptotic Cell Death by Preventing HDAC4 Up-Regulation in Neuronal Cells and in Rat Prefrontal Cortex. *Toxicol Sci*. 2016 Sep 22.
3. Colangelo T, Polcaro G, Ziccardi P, Pucci B, Muccillo L, Galgani M, Fucci A, Milone MR, Budillon A, **Santopaolo M**, Votino C, Pancione M, Piepoli A, Mazzoccoli G, Binaschi M, Bigioni M, Maggi CA, Fassan M, Laudanna C, Matarese G, Sabatino L, Colantuoni V. Proteomic screening identifies calreticulin as a miR-27a direct target repressing MHC class I cell surface exposure in colorectal cancer. *Cell Death Dis*. 2016 Feb. 25;7:e2120.
4. Colangelo T, Polcaro G, Ziccardi P, Muccillo L, Galgani M, Pucci B, Rita Milone M, Budillon A, **Santopaolo M**, Mazzoccoli G, Matarese G, Sabatino L, Colantuoni V. The miR-27a-calreticulin axis affects drug-induced immunogenic cell death in human colorectal cancer cells. *Cell Death Dis*. 2016. 25;7:e2108.
5. Guida N, Laudati G, Anzilotti S, Sirabella R, Cuomo O, Brancaccio P, **Santopaolo M**, Galgani M, Montuori P, Di Renzo G, Canzoniero LM, Formisano L. Methylmercury upregulates RE-1 silencing transcription factor (REST) in SH-SY5Y cells and mouse cerebellum. *Neurotoxicology*. 2016 Jan;52:89-97.
6. De Rosa V, Galgani M, **Santopaolo M**, Colamatteo A, Laccetti R, Matarese G. Nutritional control of immunity: Balancing the metabolic requirements with an appropriate immune function. *Semin Immunol*. 2015 Sep;27(5):300-9.
7. De Rosa V, Galgani M, Porcellini A, Colamatteo A, **Santopaolo M**, Zuchegna C, Romano A, De Simone S, Procaccini C, La Rocca C, Carrieri PB, Maniscalco GT, Salvetti M, Buscarinu MC, Franzese A, Mozzillo E, La Cava A, Matarese G. Glycolysis controls the induction of human regulatory T cells by modulating the expression of FOXP3 exon 2 splicing variants. *Nat Immunol*. 2015 Nov;16(11):1174-84.
8. Sabbatini M, Ruggiero G, Palatucci AT, Rubino V, Federico S, Giovazzino A, Apicella L, **Santopaolo M**, Matarese G, Galgani M, Terrazzano G. Oscillatory mTOR inhibition and Treg increase in kidney transplantation. *Clin Exp Immunol*. 2015 Nov;182(2):230-40.
9. Galgani M, Insabato L, Cali G, Della Gatta AN, Mirra P, Papaccio F, **Santopaolo M**, Alviggi C, Mollo A, Strina I, Matarese G, Beguinot F, De Placido G, Ulianich L. Regulatory T cells, inflammation, and endoplasmic reticulum stress in women with defective endometrial receptivity. *Fertil Steril*. 2015 Jun;103(6):1579-86.e1.
10. Guida N, Laudati G, Galgani M, **Santopaolo M**, Montuori P, Triassi M, Di Renzo G, Canzoniero LM, Formisano L. Histone deacetylase 4 promotes ubiquitin-dependent proteasomal degradation of Sp3 in SH-SY5Y cells treated with di(2-ethylhexyl)phthalate (DEHP), determining neuronal death. *Toxicol Appl Pharmacol*. 2014 Oct 1;280(1):190-8.